CJC-1295 (no DAC)
also known as CJC-1295 without DAC, Mod GRF 1-29, CJC-1295 no DAC
29-amino-acid GHRH analogue based on the active N-terminal fragment of human GHRH (GRF 1-29) with four amino-acid substitutions for stability against enzymatic degradation. Unlike CJC-1295 with DAC (Drug Affinity Complex), the no-DAC variant lacks the maleimide that binds serum albumin, giving it a short pulsatile half-life (~30 min) similar to native GHRH. Pairs naturally with selective GHRPs like ipamorelin for dual-axis GH stimulation.
At a glance
SQ · Pre-sleep · 1–2×/day
Mechanism
Primary target — Pituitary GHRH receptor [teichman-2006].
Pathway — GHRH-R → Gαs → cAMP → PKA → GH vesicle exocytosis [teichman-2006].
Downstream effect — Pulsatile GH release matching physiological pattern; subsequent IGF-1 elevation [ionescu-2006].
Origin — Modified human GRF 1-29 with four substitutions (D-Ala²/Gln⁸/Ala¹⁵/Leu²⁷) for protease resistance [teichman-2006].
Feedback intact — Yes — short pulse preserves somatostatin negative feedback [ionescu-2006].
Dosage
Protocols described in the cited literature; not medical advice.
| Parameter | Value |
|---|---|
| Standard dose | 100 mcg per injection [teichman-2006]Often paired with ipamorelin in same syringe. |
| Frequency | 1–2× daily (pre-sleep ± morning) |
| Lower / starter dose | 50 mcg per dose |
| Evidence basis | Phase 1 (CJC-1295 with DAC); analog data [teichman-2006][ionescu-2006]No-DAC variant is less studied directly; PK extrapolated from native GHRH. |
| Duration | 8–12 weeks on / 4 off (anecdotal) |
| Reconstitution | Bacteriostatic water |
| Timing | Pre-sleep + fasted preferred |
| Half-life | ~30 min [ionescu-2006]Short pulse vs CJC-1295-DAC (~8 days). Choose no-DAC for pulsatile, DAC for sustained. |
Reconstitution
A pure mass-to-volume utility. Enter what you have in the vial; the atlas computes the volume per dose. No prescription information.
Adverse events
Severities follow the FDA / CTCAE convention.
- — Active malignancy or cancer history
- — Pregnancy / breastfeeding
- — Disrupted hypothalamic-pituitary axis
- — Untreated diabetes
- — Severe insulin resistance
Administration
- 01Reconstitution
Add 2 mL bacteriostatic water to 2 mg vial → 1 mg/mL = 100 mcg per 0.1 mL. Roll gently.
- 02Injection site
Subcutaneous, abdomen or thigh. Rotate sites.
- 03Timing
Pre-sleep preferred. Often combined with ipamorelin in the same syringe.
- 04Storage
Lyophilised: room temp, protected from light. Reconstituted: refrigerate 2–8 °C, use within 30 days.
- 05Needle
29–31G, 4–8 mm insulin syringe.
Synergies
Sources
of 51 rendered claims carry a resolvable citation.
- [ionescu-2006]Ionescu 2006 — Pulsatile secretion of growth hormone induced by a new GH releasing factor analog (CJC-1295) in subjects with adult GH deficiency
J Clin Endocrinol Metab, 2006 - [raun-1998]Raun 1998 — Ipamorelin, the first selective growth hormone secretagogue
Eur J Endocrinol, 1998 - [sigalos-2018]Sigalos 2018 — The safety and efficacy of growth hormone secretagogues
Sex Med Rev, 2018 - [teichman-2006]Teichman 2006 — Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295
J Clin Endocrinol Metab, 2006